key: cord-0821414-3rg7yhpn
authors: Ahmed, M.S.; Brehme, H.; Friedrich, S.; Reinhardt, L.; Blum, S.; Beissert, S.; Meier, F.
title: COVID‐19 and immune checkpoint inhibitors
date: 2021-02-25
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.17172
sha: 4cf71cc7846e86bf643aa9d86517c0a4b332c3cd
doc_id: 821414
cord_uid: 3rg7yhpn

SARS-CoV-2 confronts physicians with critical questions, including the use of anticancer therapies in the context of a possible COVID-19 infection. Based on a case report of a patient with metastatic melanoma, the course of a COVID-19 infection under immune checkpoint inhibitor (ICI) therapy will be shown, and recent literature will be discussed.

diagnosed requiring anticoagulant therapy. An acute respiratory distress syndrome required tracheal intubation. Intensive care was required for 2 months before improvement in pulmonary function was achieved. On follow-up chest CT, pulmonary consolidation had significantly decreased (Fig. 2) . After 2 months of mechanical ventilation, the patient was successfully weaned and extubated. The patient is recovering adequately. Brain MRI showed tumour regression, without signs of extracranial metastasis in whole-body CT scan.

Cancer patients are at higher risk of infection and severe infection outcomes. However, a large cohort of cancer patients was evaluated for COVID-19 in the United States to identify risk factors for COVID-19 susceptibility in cancer patients. 1 The prevalence of COVID-19 among cancer patients appeared to be lower than in the general population despite numerous potentially risky appointments at the clinic. Immunosuppressive chemotherapies leave the patients more susceptible to infections like COVID-19. In contrast, ICIs are able to restore cellular immunocompetence. 2 However, an analysis of 423 COVID-19 cases depicted immunotherapy as an independent risk factor of severe COVID-19 pneumonia. 3 Patients receiving ICI may develop symptoms consistent with immune-related adverse events (irAEs), COVID-19 infection or both. 4 For example, a SARS-CoV-2 infected patient may present with fever, cough and dyspnea (mimicking ir pneumonitis), elevated troponin or heart 

The pulmonary changes observed in COVID-19 infection are comparable to those in ir pneumonitis and are caused by hyperactivation of the immune system, resulting in cytokine storm. Hence, patients who are more prone to develop irAEs are more likely to develop a cytokine storm in the case of SARS-CoV-2 infection characterized by a hyperinflammatory reaction with high levels of pro-inflammatory cytokines like interleukin-6 (IL-6). 5 Clinical trials investigating anti-IL-6 therapy in patients with severe COVID-19 pneumonia yielded conflicting results. [6] [7] [8] The WHO established a living guidance for the clinical management of COVID-19 and strongly recommends corticosteroids for the treatment of patients with severe COVID-19. 9 Another relevant aspect is the effect of COVID-19 related diagnostic delays in cancer patients. A recent analysis shows a reduction in long-term survival of more than 10% due to a diagnostic delay of 3 months in most cancer types. 10 This case report shows that elderly, frail patients under ICI treatment can survive a critical COVID-19 infection. Patients with an active tumour disease are facing a lethal outcome if diagnostic measures or/and tumour therapy are postponed. Patients under ICI treatment may develop symptoms possibly consistent with both irAEs or COVID-19. Several drugs are being investigated in clinical trials to treat critical COVID-19 infections. The WHO strongly recommends corticosteroids for the treatment of patients with severe COVID-19. We would like to point out that we described and discussed a single case. Multicentre retrospective studies are crucial to collect clinical data of as many patients as possible with COVID-19 and cancer to guide clinicians on management.

Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients

Determinants of COVID-19 disease severity in patients with cancer

COVID-19 and immune checkpoint inhibitors: initial considerations

Cytokine release syndrome in severe COVID-19

Efficacy of tocilizumab in patients hospitalized with COVID-19

Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia. A randomized clinical trial

Association between early treatment with tocilizumab and mortality among critically Ill patients with COVID-19

Dexamethasone and COVID-19. Geneva: World Health Organization

Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study

The patient in this manuscript has given informed consent to publication of her case details.

None.